Multiple tumorous lesions of the pituitary gland.
Adenoma
Double adenomas
Gangliocytoma
Granular cell tumor
Metastasis
Multiple tumorous lesions
PANCH
PitNETs
Pituicytoma
Pituitary
Pituitary cysts
Rathke’s cleft cyst
Spindle cell oncocytoma
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
11
2021
accepted:
19
07
2022
pubmed:
11
8
2022
medline:
3
12
2022
entrez:
10
8
2022
Statut:
ppublish
Résumé
Multiple tumorous lesions in one pituitary gland are rare and mostly described in case reports. Their incidences and combinations are defined in larger collectives. Therefore, we analyzed our large collection for double tumors and combinations of tumors, cysts, and inflammation. The German Registry of Pituitary Tumors, including cases from 1990 to 2018, served as the database. Our collection comprises a total of 16,283 cases up until the end of 2018. Of these cases, 12,673 originated from surgical and 3,610 from autopsy material. All specimens were fixed in formalin and embedded in paraffin. The sections were stained with hematoxylin-eosin and PAS. Monoclonal (prolactin, TSH, FSH, LH, and α subunit) or polyclonal (GH and ACTH) antibodies were used to detect pituitary hormones in the lesions. Since 2017, antibodies against the transcription factors Pit-1, T-Pit, and SF-1 have been used in difficult cases. The criteria of the 2017 WHO classification have been basic principles for classification since 2018 (Osamura et al. 2017). For differentiation of other sellar tumors, such as meningiomas, chordomas, or metastases, the use of additional antibodies was necessary. For these cases, it was possible to use a broad antibody spectrum. Autopsy pituitaries were generally studied by H&E and PAS sections. If any lesions were demonstrated in these specimens, additional immunostaining was performed. Multiple tumorous lesions with more than one pituitary neuroendocrine tumor (PitNET) respectively adenoma make up 1.4% (232 cases) in our collection. Within the selected cases, synchronous multiple pituitary neuroendocrine tumors (PitNETs) account for 17.3%, PANCH cases (pituitary adenoma with neuronal choristoma) for 14.7%, PitNETs and posterior lobe tumors for 2.2%, PitNETs and metastases for 5.2%, PitNETs and mesenchymal tumors for 2.6%, PitNETs and cysts for 52.2%, and PitNETs and primary inflammation for 6.0%. The mean patient age was 53.8 years, with a standard deviation of 18.5 years. A total of 55.3% of the patients were female and 44.7% were male. From 1990 to 2018, there was a continuous increase in the number of multiple tumorous lesions. From our studies, we conclude that considering possible tumorous double lesions during surgeries and in preoperative X-ray analyses is recommended.
Identifiants
pubmed: 35947342
doi: 10.1007/s42000-022-00392-9
pii: 10.1007/s42000-022-00392-9
pmc: PMC9712358
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-663Informations de copyright
© 2022. The Author(s).
Références
Endocr Connect. 2018 Aug 23;:
pubmed: 30139817
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31513261
Br J Neurosurg. 2019 Jun 17;:1-5
pubmed: 31204511
Clin Neurol Neurosurg. 2015 Dec;139:144-51
pubmed: 26473987
Endocr Pathol. 2021 Dec;32(4):473-479
pubmed: 34129177
Pituitary. 2010;13(1):8-17
pubmed: 19551516
Eur J Endocrinol. 2006 May;154(5):753-8
pubmed: 16645024
Am J Surg Pathol. 2017 May;41(5):586-595
pubmed: 28079576
J Neurosurg. 2000 Nov;93(5):753-61
pubmed: 11059654
Pituitary. 2019 Dec;22(6):620-632
pubmed: 31598814
Pituitary. 1999 May;1(3-4):243-50
pubmed: 11081204
Eur J Endocrinol. 2007 Feb;156(2):203-16
pubmed: 17287410
Pituitary. 2022 Feb;25(1):131-142
pubmed: 34463941
Hum Pathol. 2016 Jan;47(1):138-43
pubmed: 26476569
J Neurosurg. 1999 Jul;91(1):93-9
pubmed: 10389886
Med Sci Monit. 2003 Jun;9(6):CS47-52
pubmed: 12824954
Endocr Pathol. 2018 Dec;29(4):332-338
pubmed: 30215160
Neuroradiology. 2001 Sep;43(9):755-9
pubmed: 11594426
J Surg Case Rep. 2017 May 22;2017(5):rjx039
pubmed: 28560021
J Neurosurg. 1991 Feb;74(2):243-7
pubmed: 1988594
Cent Eur Neurosurg. 2009 Aug;70(3):149-53
pubmed: 19701874
World Neurosurg. 2020 Jul;139:63-69
pubmed: 32298831
BMJ Open. 2014 Jul 24;4(7):e005202
pubmed: 25059970
Cancer. 2004 Aug 1;101(3):613-9
pubmed: 15274075
Acta Neuropathol. 2006 Jul;112(1):21-8
pubmed: 16699777
J Transl Med. 2019 Oct 29;17(1):354
pubmed: 31665029
Bone. 2011 Jan;48(1):6-15
pubmed: 20643235
Surg Neurol. 1991 May;35(5):355-9
pubmed: 2028382
Indian J Endocrinol Metab. 2019 Jul-Aug;23(4):498-500
pubmed: 31741914
Acta Neurochir (Wien). 2007 Dec;149(12):1223-8
pubmed: 17914599
World Neurosurg. 2021 May;149:e51-e62
pubmed: 33647491
World Neurosurg. 2017 Oct;106:1050.e1-1050.e6
pubmed: 28532920
Pathologe. 1985 Nov;6(6):308-12
pubmed: 4088978
Pituitary. 2020 Jun;23(3):322-325
pubmed: 31834538
Neurosurgery. 1992 Nov;31(5):840-9; discussion 849
pubmed: 1331847
Acta Neurochir (Wien). 2018 Oct;160(10):1989-1999
pubmed: 30109498
Brain Tumor Pathol. 2002;19(2):63-7
pubmed: 12622135
Endocr Pathol. 2017 Sep;28(3):228-243
pubmed: 28766057
Arch Pathol Lab Med. 1985 Mar;109(3):287-9
pubmed: 2983639
Pituitary. 2017 Dec;20(6):702-708
pubmed: 28766078
Neurosurg Rev. 2020 Feb;43(1):265-272
pubmed: 30426354
Virchows Arch. 1994;425(1):93-9
pubmed: 7921420
J Cancer Res Ther. 2017 Jul-Sep;13(3):580-582
pubmed: 28862230
Front Endocrinol (Lausanne). 2019 Nov 08;10:772
pubmed: 31781041
Endocr Pathol. 1999 Jun;10(2):123-35
pubmed: 27519216
Neurosurgery. 1998 Jan;42(1):7-16; discussion 16-7
pubmed: 9442498
Mod Pathol. 2021 Sep;34(9):1634-1650
pubmed: 34017065
Acta Neuropathol. 1983;61(3-4):253-7
pubmed: 6650139
J Neurosurg. 1994 Jun;80(6):1018-25
pubmed: 8189257
Neurol Neurochir Pol. 2002 Mar-Apr;36(2):293-306
pubmed: 12046506
Clin Neurol Neurosurg. 2016 Oct;149:122-35
pubmed: 27521460
J Neurosurg. 2000 Jul;93(1):62-7
pubmed: 10883906
Ann Intern Med. 1984 Dec;101(6):789-93
pubmed: 6333843
Case Rep Otolaryngol. 2020 Sep 8;2020:9584090
pubmed: 32963865